Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125821421 | 12582142 | 1 | I | 20160708 | 20160722 | 20160722 | EXP | US-CIPLA LTD.-2016US09822 | CIPLA | 0.00 | Y | 0.00000 | 20160722 | OT | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125821421 | 12582142 | 1 | PS | CARBOPLATIN. | CARBOPLATIN | 1 | Intra-arterial | AUC 6, INFUSED FOR 30-45 MINS, EVERY SIX WEEKS CYCLE | U | 77383 | INFUSION | ||||||||
125821421 | 12582142 | 2 | SS | CISPLATIN. | CISPLATIN | 1 | Intra-arterial | 60 MG/M2, INFUSED FOR 30-45 MINS, EVERY SIX WEEKS CYCLE | U | 0 | 60 | MG/M**2 | INFUSION | ||||||
125821421 | 12582142 | 3 | SS | SORAFENIB | SORAFENIB | 1 | Oral | 400 MG, BID | U | 0 | 400 | MG | |||||||
125821421 | 12582142 | 4 | SS | SORAFENIB | SORAFENIB | 1 | Oral | 400 MG, DAILY | U | 0 | 400 | MG |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
125821421 | 12582142 | 1 | Hepatocellular carcinoma |
125821421 | 12582142 | 2 | Hepatocellular carcinoma |
125821421 | 12582142 | 3 | Hepatocellular carcinoma |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
125821421 | 12582142 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125821421 | 12582142 | Hepatic encephalopathy |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |